Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Hikma Pharmaceuticals LLC
- Enrollment
- 30
- Locations
- 2
- Primary Endpoint
- Proportion of patients with AEs and SAEs (including laboratory abnormalities).
Study Overview
Brief Summary
The purpose of this observational study is to evaluate the Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients with Relapsing-Remitting Multiple Sclerosis in Egypt
Detailed Description
This is an observational, prospective, cohort study, where no visits or intervention(s) additional to the daily practice will be performed. In the study sites, patients undergoing routine clinical care for RRMS and initiating treatment with generic Fingolimod in accordance with the approved summary of product characteristics (SPC) will be followed up and assessed for a total of 12 months.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients who initiate treatment with generic Fingolimod at baseline in accordance with the approved summary of product characteristics (SPC).
- •Males and females who are ≥ 18 years old.
- •Patients who had a diagnosis of RRMS per 2010 or 2017 revised McDonald criteria, who are:
- •Newly diagnosed who had no prior Disease-Modifying Therapy (DMT), or
- •Switched patients from Gilenya®, Novartis, or
- •Switched patients from interferon beta (IFNβ).
- •Patients who agree to participate in the study and provide a written informed consent.
Exclusion Criteria
- •Pregnant or lactating female patients and women of childbearing potential not using effective contraception.
- •Patients lacking immunity against varicella zoster virus (VZV).
- •Patients participating in other clinical studies.
- •Patients who meet any of the contraindications to the administration of the study drug according to the approved SPC.
Outcomes
Primary Outcomes
Proportion of patients with AEs and SAEs (including laboratory abnormalities).
Time Frame: up to 12 months from initiating generic Fingolimod.
Proportion of patients experiencing a relapse.
Time Frame: Time frame: up to 12 months period from initiating generic Fingolimod.
Time to First Relapse (TTFR)
Time Frame: up to 12 months from initiating generic Fingolimod.
Proportion of patients with disability progression as measured by the EDSS over time.
Time Frame: up to 12 months from initiating generic Fingolimod.
Secondary Outcomes
- Proportion of patients with AEs and SAEs (including laboratory abnormalities) leading to treatment discontinuation.(up to 12 months from initiating generic Fingolimod.)